Synergy Pharmaceuticals to Present at ROTH 24th Annual Growth Conference
March 07, 2012 08:53 ET
|
Synergy Pharmaceuticals
NEW YORK, March 7, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, today...
Synergy Pharmaceuticals to Present at 32nd Annual Cowen and Company Health Care Conference
February 29, 2012 16:00 ET
|
Synergy Pharmaceuticals
NEW YORK, Feb. 29, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), (Nasdaq:SGYPU), (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases,...
Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
December 13, 2011 09:00 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (Nasdaq:SGYPD, SGYPU), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has filed a lawsuit in New York...
Synergy Pharmaceuticals Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
December 13, 2011 04:41 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (Nasdaq: SGYPD, SGYPU), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the full exercise of the over-allotment option...
Synergy Pharmaceuticals Inc. Announces Pricing of Public Offering of 1,875,000 Units, Listing on NASDAQ and Effectiveness of Reverse Stock Split
December 01, 2011 08:00 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (NASDAQ: SGYPD), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the pricing of an underwritten public offering of...
Synergy Pharmaceuticals Raises $5.64 Million in Financing
November 15, 2011 05:30 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTCQB:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has completed a financing in which it...
Synergy Pharmaceuticals and Fox Chase Cancer Center Presentation at 2011 ACG Meeting Highlights Potential of GC-C Agonists to Delay Progression of Colitis into Colon Cancer
October 31, 2011 06:00 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTC QB: SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that poster P409 presented at the upcoming 2011...
Synergy Pharmaceuticals Presentations at 2011 American College of Gastroenterology Annual Scientific Meeting
October 27, 2011 10:41 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTC QB:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced the presentation of three posters on plecanatide...
Synergy Pharmaceuticals Initiates Dosing of Patients in Phase II/III Trial of Plecanatide in Chronic Constipation
October 24, 2011 06:00 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTC QB: SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced initiation of dosing of patients in a major...
Synergy Pharmaceuticals to Present at Jefferies 2011 Global Healthcare Conference
June 03, 2011 04:21 ET
|
Synergy Pharmaceuticals
NEW YORK--Synergy Pharmaceuticals, Inc. (OTC QB: SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that Dr. Gary S. Jacob, President and Chief...